Nilo Therapeutics raises $45M seed from Gates Frontier, Lux Capital, DCVC Bio and Alexandria for neural immune circuit targeting
Summary
Nilo Therapeutics raised $45M in seed financing from Gates Frontier, Lux Capital, DCVC Bio, and Alexandria Venture Investments to develop pharmacological and bioelectronic modulation of vagal neural circuits that regulate systemic immune activation. Founded by three of the world's top neuroscientists (Columbia's Charles Zuker, Yale's Ruslan Medzhitov, Harvard's Steve Liberles) in collaboration with The Column Group, Nilo targets autoimmune and inflammatory diseases where the neural regulation of immunity offers a novel therapeutic approach.
Why it matters
Gates Frontier and Lux Capital co-leading a $45M seed for a company targeting neural immune circuits represents one of the highest-conviction early-stage bets in neuroimmunology. The founding scientist trio — Zuker (taste circuits), Medzhitov (innate immunity), Liberles (interoception) — brings the most relevant combination of neuroscience and immunology expertise to the vagal immune circuit problem.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial